Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Open Access
- 24 November 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 586572
- https://doi.org/10.3389/fimmu.2020.586572
Abstract
COVID-19 pandemic has infected millions of people with mortality exceeding >1 million. There is an urgent need to find therapeutic agents that can help clear the virus to prevent severe disease and death. Identifying effective and safer drugs can provide more options to treat COVID-19 infections either alone or in combination. Here, we performed a high throughput screening of approximately 1,700 US FDA-approved compounds to identify novel therapeutic agents that can effectively inhibit replication of coronaviruses including SARS-CoV-2. Our two-step screen first used a human coronavirus strain OC43 to identify compounds with anti-coronaviral activities. The effective compounds were then screened for their effectiveness in inhibiting SARS-CoV-2. These screens have identified 20 anti-SARS-CoV-2 drugs including previously reported compounds such as hydroxychloroquine, amlodipine besylate, arbidol hydrochloride, tilorone 2HCl, dronedarone hydrochloride, mefloquine, and thioridazine hydrochloride. Five of the newly identified drugs had a safety index (cytotoxic/effective concentration) of >600, indicating a wide therapeutic window compared to hydroxychloroquine which had a safety index of 22 in similar experiments. Mechanistically, five of the effective compounds (fendiline HCl, monensin sodium salt, vortioxetine, sertraline HCl, and salifungin) were found to block SARS-CoV-2 S protein-mediated cell fusion. These FDA-approved compounds can provide much needed therapeutic options that we urgently need during the midst of the pandemic.This publication has 46 references indexed in Scilit:
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Identification of a novel coronavirus causing severe pneumonia in human: a descriptive studyChinese Medical Journal, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Genotype shift in human coronavirus OC43 and emergence of a novel genotype by natural recombinationJournal of Infection, 2014
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaThe New England Journal of Medicine, 2012
- Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with PneumoniaJournal of Virology, 2005
- A Novel Coronavirus Associated with Severe Acute Respiratory SyndromeThe New England Journal of Medicine, 2003
- Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory SyndromeThe New England Journal of Medicine, 2003
- Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease.Proceedings of the National Academy of Sciences of the United States of America, 1967